Press Releases
Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from...
Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that results from an interim analysis of its Phase III, randomized, open-label ELOQUENT-2 trial were...
Press Releases
Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 36th Annual Global Health Care Conference on Tuesday, June 9, 2015, in Rancho Palos...
Press Releases
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA)...
Press Releases
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously...
Press Releases
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy...
Press Releases
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have entered into a clinical trial collaboration to evaluate the...
Press Releases
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read